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Advances in Technology 




Edison T. Liu, M.D.∗ 
We are entering one of the most profound periods of human advancement.  One 
that is predicated on the benefits of science and one that can potentially change the 
nature of human health through direct intervention. Whereas our efforts have 
previously been to treat illness, our technologies in the near future, by 
understanding and harnessing human complexity, will also be able to replace and 
correct what was previously unfixable, and to enhance human performance. 
Fundamental to these new approaches is the precise knowledge of the molecular 
causes of human disease, and the ability to engineer chemical, biological, or 
mechanical solutions to alter these targets.  With the advent of high throughput 
screening approaches, genomics, informatics, combinatorial chemistry, and 
automation, the speed of biological discovery has increased by thousands to a 
million fold.  This speed of discovery has had a profound impact on the 
development of precise diagnostic biomarkers, and in developing new drug 
therapeutics by the pharmaceutical and biotechnology sectors. 
The progress in pharmaceutical is well exemplified in the field of cancer. For 
example, with the introduction of combination chemotherapy in childhood 
leukemias, and in testicular cancers in young men, the overall mortality from these 
cancers has fallen by almost 60%.  This has been primarily due to intelligent 
combinations of chemotherapeutic agents.  More recently, however, the focus of 
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the pharmaceutical industry in cancer therapeutics has been towards therapeutics 
specifically targeted at defined molecules as compared to the more indiscriminate 
approach of inducing DNA damage as had been the case for cytotoxic agents of the 
past.  New drugs synthesized to target one class of enzymes, the kinases, are 
effective treatments for certain cancers.  The introduction of Gleevec as a targeted 
anti-kinase therapeutic for chronic myelogenous leukemia (CML) has significantly 
reduced mortality from this disease by almost 50%.  In all examples given, these 
were the first reductions in cancer mortality ever documented on a population scale 
and are reflected in the significant improvement in national health statistics.  
Though prevention and early diagnosis contributed to these improvements in 
mortality rates, for cancers such as the leukemias and testicular cancers, they are 
completely attributable to dramatically improved therapies.  Thus, dramatic 
advances in biology and technology have fundamentally changed medicine and the 
health care landscape mainly in the last twenty-five years. 
In the 21st century, some of the changes that have taken place in science and 
society will significantly alter how the pharmaceutical business will be conducted.  
Scientifically, the breakthrough developments are in computational biology, 
genomics, combinatorial chemistry, and automation.  The sequencing of complete 
genomes including those of humans and important animal models, such as the 
mouse and the rat, has revolutionized the concept of target identification.  In the 
past, each potential drug target represented by the protein product of a gene was 
cloned using laborious molecular approaches.  The availability of complete 
genome sequences and full length cDNA (representing the expressed messenger 
RNA) sequences enables investigators to clone a gene and related molecules with 
remarkable speed by bypassing physical screening of a genomic library.  Advances 
in combinatorial chemistry provide immense structural diversity for biologists to 
work with so that millions of unique compounds can be generated and screened 
rather than only tens of compounds. Structural and computational chemistry has 
progressed such that any protein target can be virtually assessed for potential 
chemical inhibitors.  Thus, strong candidate drugs can be designed computationally 
eliminating potentially wasteful wet laboratory experimentation. 
The unifying technologies that underlie the genomics and the chemistry are 
derived from computational advances and from automation.  All genomic and 
pharmaceutical chemistry challenges are being addressed using some form of high 
capacity computing and employing advanced devices, including robots. The 
computational advances include electronic communications which allows for 
scientists and administrators from geographically distant sites to work closely 
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together.  Taken together, the scale of the information and the laboratory research 
activities has increased by orders of magnitude – thousands to million of times 
faster and more comprehensive in scope. What research units are pursuing is the 
reconstruction of all the signal “wiring” of a cell (such as a cancer cell) so that 
outcomes can be predicted.  In many ways, like how aircraft design has progressed, 
biology and pharmaceutics are emerging from a state where trial and error was 
standard operating procedure to one where new designs are modeled 
computationally before a prototype is built. 
These fundamental changes in the conduct of biological investigations have 
driven concomitant shifts in those management systems and the organizational 
structures that historically fired the success of the biotechnology and the 
pharmaceutical industry.  For example, biotechnology companies emerged 
primarily because pharmaceuticals were centered on chemistry and could not 
readily harness or manage discovery based on molecular biology.  As a result, 
companies rose to provide solutions in discovering targets for diseases.  Exelixis, 
Affymetrix, Celera were all companies based on platform technologies that 
serviced big pharma. Similarly, other biotechnology companies focused on 
recombinant engineering in generating biotherapeutics such as therapeutic 
antibodies and therapeutic proteins.  Here Genentech (recombinant insulin) and 
Amgen (recombinant erythropoietin) were the big names.  But now, because of 
current technologies, discovery and recombinant production are no longer the 
limiting steps.  Genomics enabled easy mining of targets; but validation of these 
targets as to which one is the most important has become the focus.  Recombinant 
engineering is now a standard technology adopted by all pharmaceuticals.  So the 
new biotechnology companies have become more computational providing 
structural solutions, and late stage developers of selected compounds that have 
been abandoned by failed biotech companies or left to languish by big pharma.  
Technology has changed the focus of biopharmaceuticals. 
Equally important, these enabling technologies are also altering the way nations 
govern, develop, and market their biomedical strategies.  Since some of these 
technologies have become boilerplate, nations have found it lucrative to provide 
technical services to pharmaceutical and biotechnology companies at a low price.  
India and China are offering antibody production and generation of recombinant 
proteins and chemistry to the world; and their governments are supporting this 
development.  Though boilerplate, the processes are complex and require higher 
technical expertise.  The cost differential in salaries for PhDs and engineers in 
these developing countries make outsourcing to them very competitive.  Moreover, 
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contemporary telecommunications with its wide-bandwidth and improved air 
travel to these sites allow for outsourcing to not only be cost effective but 
convenient as well. 
So given these developments, where will the pharmaceutical industry be in the 
21st century?  First, the entire industry will need to bring products to the market 
much more quickly; these products must be cheaper, and will need to be safer than 
current drugs are. This trend is not because of market forces, but rather because of 
demands of social justice.  In the past, the United States was the major market for 
pharmaceutical products in the world.  Though Europe and Japan has risen in the 
post-war era to be major pharma markets, the US still dominates the market.  This 
is primarily due to a health financing system of subsidized free enterprise which 
has allowed for unchecked rises in health care costs.  In 2002, health care 
consumed 15% of the US G.D.P. and is projected to be 18% in 2012, as compared 
to about 9% for Europe, Japan, and Canada, and 3% in Singapore.  Health care 
costs for pensioners have become a major financial burden that jeopardizes the 
competitiveness and viability of US companies.  Moreover, as the population ages, 
the burden onto Medicare will further exacerbate an already problematic Social 
Security system.  Thus, this rise in health care costs in the US is untenable and 
cannot be supported in the future.  Drug costs will be progressively controlled 
either directly by governments (even in the US), or indirectly because of political 
demands.  This, in turn, puts pressure on the pharmaceutical industry to be more 
efficient in developing drugs to maintain profit margins and shareholder value. 
 Paradoxically, despite these financial and social demands, the trends in the 
pharmaceutical industry have been in the opposite direction. The pipeline of many 
companies has been of concern sparking a wave of mergers; the time to market has 
increased significantly, and the costs for development have skyrocketed.  There 
will progressively be greater pressure on the pharmaceuticals by shareholders and 
by governments to provide cheaper drugs which means faster development and 
lower development costs.  Simultaneously, the sophistication of many drug 
markets, including the emerging markets in China and India, places increasing 
regulatory demands for safety in these countries.  The question therefore, is how to 
provide more drugs that are better, safer and less expensive?  The answer, found in 
other industries from financial services to airline construction, is in technology and 
in globalization. 
Certainly, as mentioned before, complex but modular tasks in the drug 
development path such as chemistry, toxicology, and clinical trials can now be 
outsourced to lower-cost regions on a global scale without a concomitant loss of 
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quality.  Therefore Eastern Europe, Ireland, China, India, Taiwan, and Singapore 
have all have benefited from this outsourcing trend in pharmaceuticals; so much 
so, that most of these countries have specific governmental plans to develop 
pharmaceuticals as a means to diversify their economies.  Unlike standard 
manufacturing, pharmaceutical development has more stringent quality control 
requirements and, therefore, successful entrants have had a strong focus on higher 
education.  Because the modularity makes it easy for multinational 
pharmaceuticals to shift sites quickly, there is intense competition amongst the 
entrants to maintain a competitive edge. 
 The second trend in pharmaceuticals will be to exploit complexity.  
Biologists have always known living systems to be very complex, but until 
recently, have not been able to precisely identify the components and their working 
relationships.  The computational advances have provided solutions to many of 
these challenges.  At the same time, chemistry is now very precise in targeting 
specific molecules.  This combination of the detailed mapping of complex systems 
and precisely targeted chemical inhibitors has opened the possibility of using 
combinations to tailor treatments.  This realm of combinatorics, whereby 
combinations of different drugs at different doses tailored for the unique 
physiologic composition of an individual patient, is progressively a reality.  
Pharmaceutical companies, previously focused on pushing single chemical entities, 
will need to develop combinations very early in the developmental cycle.  Since 
combinations of drugs exponentially increase the possibilities of therapeutic 
interventions, the demand for quickly completing clinical trials will be great.  
Moving these trials from North America and Europe will not only be cost-effective 
but essential, given the number of patients needed.  Again, globalization of the 
development process is the solution. 
Finally, all these new research and business models spawned by advanced 
technologies in a global field will need to be managed to maximize output.  
Financial markets have readily adopted communication technologies to their 
advantage.  The transactional nature of their business, where massive bits of 
information need to be transferred securely, is well suited for the technologies 
available.  By contrast, the business of creation, which is the fundamental of 
research and discovery in biomedicine, is more ephemeral and requires different 
forms of management.  But there are distinct trends. 
Outsourcing research in the form of contract research in a creation intensive 
environment is not optimal. Pharmaceutical companies instead have used a 
strategy of establishing multiple research sites that span many continents, each 
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playing distinctive and important roles in the creation process.  IBM has pursued 
this in their many centers of excellence, each with an area of focus.  Eli Lilly has a 
number of research units in Europe and Singapore to amplify their capabilities in 
Indianapolis.  Often, the research units are a product of an acquisition, but more 
frequently these will be part of a larger strategy to exploit specific concentrations 
of expertise, or simply to globally distribute sensors of new thinking.  This last 
reason tacitly acknowledges that no single center is the sole well-spring of creative 
potential, and that a company is wise to “harvest” new ideas and concepts from 
thought leaders anywhere in the world.  This is best done not by traveling 
programme directors, but by forming research roots in regional research 
communities. 
If structured appropriately, these distributed sensors can also advise the 
corporate leaders on opportunities based on leveraging differences in social and 
health care preferences of different regions.  A simple example has been the 
shifting of animal-based research from UK sites where animal rights activists are 
disruptive to regions where animal experimentation is more accepted, such as the 
United States.  Similarly, more companies focusing on stem cells are relocating 
from the US with its restrictive regulations against stem cell research to other 
jurisdictions more favorably inclined, such as Europe and Singapore.  A more 
complex situation, however, might be to explore the following: Asian patients pay 
out of pocket for diagnostic tests – technologies used in diagnostics can be 
manufactured more cheaply in Asia where regulations around diagnostics are less 
restrictive, and investors appear to be more willing to fund biomarker companies in 
Asia than in the West.  Therefore, it may be advantageous to manufacture and 
market new diagnostics first in Asia.  Later, at a favorable time, the same 
diagnostic may be introduced in the US and EU.  This form of “social arbitrage” 
takes advantage of differentials in social preferences to advance therapies for 
human disease.  This strategy should not be interpreted as supporting unethical 
testing in regulatory lax jurisdictions, which cannot be condoned.  However, it is 
clear that for historical and social reasons, different societies are more or less 
enthusiastic or cautious about certain practices and place greater regulatory 
constraints (e.g. stem cell research in the US, recombinant engineering in 
Germany, animal experimentation in the UK).  These differences can be used to 
optimize pharmaceutical development. 
Taken together, advanced technologies have already dramatically changed the 
landscape of drug discovery.  It has accelerated discovery by orders of magnitude 
and carries a promise of bringing better and safer drugs to the market.  Technology 
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also has facilitated globalization, which in turn will help develop safe drugs faster.  
Without this increase in efficiency and throughput, the pharmaceutical industry 
will face a challenge of survival.  Finally, globalization, if harnessed correctly, can 
bring the economic and social benefits of biomedicine to a much wider audience 
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